CN101321744A - 作为回旋酶抑制剂的苯并咪唑衍生物 - Google Patents

作为回旋酶抑制剂的苯并咪唑衍生物 Download PDF

Info

Publication number
CN101321744A
CN101321744A CNA2006800454440A CN200680045444A CN101321744A CN 101321744 A CN101321744 A CN 101321744A CN A2006800454440 A CNA2006800454440 A CN A2006800454440A CN 200680045444 A CN200680045444 A CN 200680045444A CN 101321744 A CN101321744 A CN 101321744A
Authority
CN
China
Prior art keywords
compound
ring
cor
unit
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800454440A
Other languages
English (en)
Chinese (zh)
Inventor
P·查里夫森
D·丹宁格
J·德鲁姆
A-L·戈里洛特
A·勒迪尔安
廖友胜
E·佩罗拉
S·隆金
D·斯塔默斯
王天生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CN101321744A publication Critical patent/CN101321744A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2006800454440A 2005-11-07 2006-11-06 作为回旋酶抑制剂的苯并咪唑衍生物 Pending CN101321744A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73413905P 2005-11-07 2005-11-07
US60/734,139 2005-11-07

Publications (1)

Publication Number Publication Date
CN101321744A true CN101321744A (zh) 2008-12-10

Family

ID=37894258

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800454440A Pending CN101321744A (zh) 2005-11-07 2006-11-06 作为回旋酶抑制剂的苯并咪唑衍生物

Country Status (7)

Country Link
US (1) US8394803B2 (https=)
EP (1) EP1948635A1 (https=)
JP (1) JP2009514894A (https=)
CN (1) CN101321744A (https=)
AU (1) AU2006311729A1 (https=)
CA (1) CA2626685A1 (https=)
WO (1) WO2007056330A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103384665A (zh) * 2011-01-14 2013-11-06 沃泰克斯药物股份有限公司 制备促旋酶和拓扑异构酶抑制剂的方法
CN104945329A (zh) * 2014-03-24 2015-09-30 中国医学科学院医药生物技术研究所 抗结核药物及抗结核药物筛选方法

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582641B2 (en) 2003-01-31 2009-09-01 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US8404852B2 (en) 2003-01-31 2013-03-26 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7569591B2 (en) 2003-01-31 2009-08-04 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7618974B2 (en) 2003-01-31 2009-11-17 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
US8193352B2 (en) 2003-01-31 2012-06-05 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
MX2010006237A (es) 2007-12-07 2010-12-21 Vertex Pharma Formas solidas de 1-etil-3-(5-(5-fluoropiridin-3-il)-7-(pirimidin- 2-il)-1h-benzo[d]imidazol-2-il)urea.
WO2010027583A1 (en) 2008-09-03 2010-03-11 Universal Display Corporation Phosphorescent materials
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
WO2010111058A1 (en) * 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
US9221765B2 (en) 2009-06-10 2015-12-29 North Carolina State University Inhibition and dispersion of bacterial biofilms with benzimidazole derivatives
BR112012024705A2 (pt) 2010-03-31 2016-06-07 Actelion Pharmaceuticals Ltd derivados antibacterianos de isoquinolin-3-ilureia
WO2011151620A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
WO2011151618A2 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile-associated disease
WO2011151617A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
ES2568455T3 (es) 2010-06-01 2016-04-29 Summit Therapeutics Plc Compuestos para el tratamiento de enfermedad asociada a Clostridium difficile
WO2011151619A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
WO2012097270A1 (en) 2011-01-14 2012-07-19 Vertex Pharmaceuticals Incorporated Solid forms of gyrase inhibitor (r)-1-ethyl-3-[5-[2-{1-hydroxy-1-methyl-ethyl}pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl}-1h-benzimidazol-2-yl]urea
US8476281B2 (en) 2011-01-14 2013-07-02 Vertex Pharmaceuticals Incorporated Solid forms of gyrase inhibitor (R)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-yl]urea
AU2012205415B2 (en) 2011-01-14 2017-02-02 Spero Therapeutics, Inc. Pyrimidine gyrase and topoisomerase IV inhibitors
AR088729A1 (es) 2011-03-29 2014-07-02 Actelion Pharmaceuticals Ltd Derivados de 3-ureidoisoquinolin-8-ilo y una composicion farmaceutica
CN103702994B (zh) * 2011-06-20 2016-03-23 沃泰克斯药物股份有限公司 旋转酶和拓扑异构酶抑制剂的磷酸酯
WO2014015105A1 (en) 2012-07-18 2014-01-23 Vertex Pharmaceuticals Incorporated Solid forms of (r)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1h-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
MX2016010057A (es) 2014-02-03 2017-04-27 Spero Gyrase Inc Compuestos antibacterianos.
WO2016127102A2 (en) 2015-02-06 2016-08-11 Ernesto Abel-Santos Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis
CA3057431A1 (en) 2017-03-24 2018-09-27 Taisho Pharmaceutical Co., Ltd. 2(1h)-quinolinone derivative
KR102737283B1 (ko) 2019-07-17 2024-12-03 서밋 (옥스포드) 리미티드 리디닐라졸 및 이의 결정 형태의 제조방법
CN111658646B (zh) * 2020-06-28 2021-03-02 河南工业大学 2,6-双(2-苯并咪唑基)吡啶在制备耐碳青霉烯类铜绿假单胞菌感染药物中的应用
GB202100470D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Solid tablet dosage for of ridinilazole
GB202100471D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Preparation of antibacterial compounds
EP4398890A4 (en) 2021-09-09 2025-07-30 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The Univ Of Nevada Las Ve C. Difficile Spore Germination Inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0303494A3 (en) * 2000-12-15 2009-08-28 Vertex Pharma Parmaceutical compositions containing bacterial gyrase inhibitors and uses thereof
DE60309701T2 (de) 2002-06-13 2007-09-06 Vertex Pharmaceuticals Inc., Cambridge 2-ureido-6-heteroaryl-3h-benzoimidazol-4-carbonsäurederivate und verwandte verbindungen als gyrase und/oder topoisomerase iv inhibitoren zur behandlung von bakteriellen infektionen
US7569591B2 (en) * 2003-01-31 2009-08-04 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7618974B2 (en) 2003-01-31 2009-11-17 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
AR042956A1 (es) * 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
US7582641B2 (en) 2003-01-31 2009-09-01 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103384665A (zh) * 2011-01-14 2013-11-06 沃泰克斯药物股份有限公司 制备促旋酶和拓扑异构酶抑制剂的方法
CN103384665B (zh) * 2011-01-14 2018-01-09 斯派罗吹耐姆公司 制备促旋酶和拓扑异构酶抑制剂的方法
CN104945329A (zh) * 2014-03-24 2015-09-30 中国医学科学院医药生物技术研究所 抗结核药物及抗结核药物筛选方法
CN104945329B (zh) * 2014-03-24 2017-09-01 中国医学科学院医药生物技术研究所 抗结核药物

Also Published As

Publication number Publication date
JP2009514894A (ja) 2009-04-09
AU2006311729A1 (en) 2007-05-18
WO2007056330A1 (en) 2007-05-18
US20130030004A1 (en) 2013-01-31
US8394803B2 (en) 2013-03-12
CA2626685A1 (en) 2007-05-18
EP1948635A1 (en) 2008-07-30

Similar Documents

Publication Publication Date Title
CN101321744A (zh) 作为回旋酶抑制剂的苯并咪唑衍生物
KR100944645B1 (ko) 자이라제 억제제 및 이를 포함하는 약제학적 조성물
EP1511482B1 (en) 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections
JP4691033B2 (ja) ジャイレース阻害剤およびその用途
AU2012205419B2 (en) Solid forms of gyrase inhibitor (R)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl) pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-yl]urea
US20240208965A1 (en) Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
JP2010528021A (ja) キナーゼのインヒビターとして有用なチアゾールおよびピラゾール
KR20140037031A (ko) 피리미딘 자이라제 및 토포이소머라제 ｉｖ 억제제
AU2012205416B2 (en) Solid forms of gyrase inhibitor (R)-1-ethyl-3-(5-(2-{1-hydroxy-1-methyl-ethyl}pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl}-1H-benzimidazol-2-yl)urea
WO2014015105A1 (en) Solid forms of (r)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1h-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof
HK1124589A (en) Benzimidazole derivatives as gyrase inhibitors
NZ612912B2 (en) Solid forms of gyrase inhibitor (r)-1-ethyl-3-[5-[2-{1-hydroxy-1-methyl-ethyl}pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl}-1h-benzimidazol-2-yl]urea
NZ612918B2 (en) Solid forms of gyrase inhibitor (r)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl) pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1h-benzimidazol-2-yl]urea
WO2007030617A1 (en) Inhibitors of bacterial impdh

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1124589

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20081210

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1124589

Country of ref document: HK